Grünenthal and DKSH Expanded Pain Therapy Access
A new partnership will bring four established pain medications to patients across eight Asia-Pacific markets.
Updated on Sept. 28, 2026 in Arthritis
Live Poll
Do you trust that new corporate partnerships will improve patient access to essential pain medications?
Grünenthal and DKSH have entered a partnership to distribute four pain medications throughout Asia-Pacific, addressing the region's rising demand for chronic pain care. This agreement aims to expand regional access to these therapies by leveraging the existing manufacturing and distribution infrastructure of both companies.
Why it matters
Chronic pain presents a major healthcare challenge in the Asia-Pacific region, driven by an aging population and increasing rates of chronic disease. This partnership aims to streamline the availability of established pain management options in these markets.
The partnership involves the regional commercialization of four pain-management products, including Qutenza (an 8% topical system), Vimovo, Palexia (indicated for use in patients 6 years and older), and Zomig (indicated for use in patients 12 years and older).
The players
Grünenthal
A global research-based pharmaceutical company focused on the development of pain management therapies.
DKSH
A market expansion services provider that assists healthcare companies in commercializing products across the Asia-Pacific region.
The details
Under this agreement, DKSH will oversee the marketing, medical affairs, sales, and distribution processes for the four medications within the eight specified markets. Grünenthal will utilize its integrated global manufacturing network to produce the therapies. DKSH is now tasked with seeking local regulatory marketing authorizations for these products in Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam.
Timeline
Grünenthal and DKSH first established their partnership in 2023.
The companies announced the new agreement on September 28, 2026.
Health Landscape
This agreement builds upon the 2023 commercialization partnership between Grünenthal and DKSH, broadening the scope of therapies and territories covered by their initial joint efforts. It reflects a strategic effort to consolidate distribution networks for established pain medications in high-growth, aging populations.
If you live in the affected regions and currently manage chronic pain, these upcoming regulatory filings may eventually improve the local availability of these specific medications. You should consult with your physician to discuss whether these therapies are appropriate for your specific treatment plan.
The takeaway
Reliable access to established pain therapies is essential for managing the long-term impact of chronic conditions. Patients should maintain an ongoing dialogue with their care team regarding any changes in treatment access or the introduction of new therapeutic options in their local area.
Further reading
Learn more about managing chronic joint conditions in our Arthritis section.
Live Poll
Do you trust that new corporate partnerships will improve patient access to essential pain medications?
